This article presents the epidemiology, pathogenesis, clinical features, diagnostic criteria, treatment, and pathogenesis of tinea cruris. It also presents the terminology of tinea cruris and the treatment for tinea cruris.
The preferred treatments for tinea cruris consist of either topical antifungal agents or the drug oral terbinafine. Systemic or intramuscular application may be used on a case by case basis if the topical treatment fails. This article describes, in detail, the pharmacologic treatment of tinea cruris. This article is part of the USMLE USMLE Step 1 and 2 Exams on Medical Dermatology.
Out of every 1,000 US adolescents, it is thought that about 10 will develop pityriasis versicolor. When it happens, it can be severe and requires medication. It is also thought to occur approximately every one out of 6,000 males. Tinea cruris is classified under scalp in the ICD-10-CM.\n
On clinical grounds, patients should be asked if they are suffering from scaling of their palms and soles and, if so, what are the signs, symptoms, and duration of the condition. These signs are a form of hyperkeratosis. The key question here is to ascertain whether the patient has a systemic disease (tinea, scabies, yaws or leprosy). Patients with chronic scaling may be at increased risk of hyperkeratosis due to their increased exposure to the skin.
Tinea cruris was seen to have a cure rate of 96.4% after a single dose of oral griseofulvin therapy. This is the first study to describe cure rates as high as that and longer than the standard three-week course of griseofulvin to date. However, a longer course of griseofulvin may be associated with significant adverse effects. Although griseofulvin is a very effective and safe therapy, the cost of the drug and the potential for significant adverse effects make the use of griseofulvin in the long term clinically implausible.
It is recommended that those with symptoms of tinea cruris be screened for tinea pedis. If lesions are present this confirms the diagnosis of tinea cruris. If there are no lesions on an examination, then a two-week course of treatment may be considered. Alternatively a small number of patients are treated with oral thrush medications alone.
[Power(http://www.withpower.com/clinical-trials/tinea-cruris) can help you to find information on recent trials by treatment mode and tinea cruris type. Uhe-103 cream seems to be effective in the treatment of patients with tinea cruris and improves the quality of life of these patients.
It is important to understand the effects of uhe-103 cream because there is a range of possible results. It is important to consider the treatment of other skin disorders or conditions that may be present when using this cream.
Patients diagnosed with tinea cruris should be treated by a physician, preferably with at least a three-week course of topical minocycline. These patients should also be instructed about other treatments, particularly topical treatments, and instructed to follow-up with physicians with whom they are regularly scheduled to see for another evaluation about one and two years later. Once their warts go away, they should not try to treat them with drugs that would harm them (such as benzoyl penicillin) and should not return to get a cure because they might get a new infection.
A 3% uhe-103 cream may help to reduce irritation in patients with tinea cruris. The treatment duration of 4 weeks in this study was too short to observe a significant difference in disease progression.
Uhe-103 cream effectively treats pityriasis versicolor. The therapeutic effect of the uhe-103 cream can be observed after 4-7 days treatment. And the therapeutic effect is not significantly correlated with patient's age.
A topical formulation of the peptide uhe-103 could be used to treat inflammatory conditions, such as tinea cruris and tinea pedis. We anticipate that uhe-103 cream could be effective in improving the clinical symptoms of these conditions.